1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6577D9D0B57E7E51B85256EBC006C5B5B
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/identifying-and-evaluating-potential-products-in-driving-growth-through-new-product-planning-and-strategic-alliances?opendocument
18
19opendocument
203.84.139.101
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Sales and Marketing Strategic Alliances Identifying and Evaluating Potential Products Identifying Potential Products

Identifying and Evaluating Potential Products in Driving Growth through New Product Planning and Strategic Alliances

DB Image

ID: 4681


Features:

Metrics, Graphics


Pages/Slides: 20


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Study Overview

Knowing how to most effectively identify and evaluate potential products and how to establish decision goals for products to ensure efficiency and accountability is a necessity for any pharmaceutical company. Having a formalized selection process also improves the speed and quality of development effort. This document can help pharmaceutical companies keep the process of identifying and evaluating new products moving forward by being aware of key internal milestones. It is increasingly necessary for companies to set formal rules and processes that facilitate compound movement through the selection process from development to FDA submission. This 20-page document describes how leading pharmaceutical companies establish an integrated, systematic approach, coordinating activities and resources between different departments to move the compound through as quickly as possible.

Key Topics

  • Identifying Potential Products
  • Evaluating Potential New Products

Sample Best Practices
  • Utilize diverse channels to identify strategic alliance opportunities *One benchmark partner, for example, discovers opportunities primarily via contacts made at various meetings, conferences, and associations.
  • Concentrate strategic alliance expertise on best-known therapeutic areas
    * Another studied company, for example, stresses the importance of therapeutic-area expertise in its strategic alliances.
  • Formalize selection process to improve speed and quality of development effort.
    * Another studied company analyzes the merits of each of its compound carefully. From the beginning of the selection process the company uses a carefully planned process model.
Methodology
The insights and best practices showcased in this report are distilled from lessons learned in interviews with executives and specialists who have extensive experience in designing and managing new product planning and strategic alliance departments at a range of pharmaceutical companies. This document originated from a Best Practices, LLC consulting project.

Industries Profiled:
Pharmaceutical; Biotech; Health Care


Companies Profiled:
Eli Lilly; Pfizer; Amgen; Janssen

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.